EGFR and non-small cell lung carcinoma: In addition, osimertinib demonstrates superior efficacy compared to the first-line EGFR TKIs in advanced NSCLC patients with EGFR mutations (18.9 vs. 10.2 months) and prolongs the overall survival significantly (38.6 months in osimertinib group vs. 31.8 months in the comparator group), with a similar safety profile and lower rates of serious adverse events (Soria et al., 2018; Ramalingam et al., 2020).